JPM Week rewind: M&A, mixed signals, and CEO chats

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Greetings from San Francisco! Another JPM Week is in the books. I am very ready to fly home today for some rest and quality Bo time. I think there’s a winter beach trip in his near future.

Read on for some of my JPM25 musings. I have a notebook full of reporting, and I’ll have even more to share next week.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

With medical debt burdening millions, a financial regulator steps in to help

When President Barack Obama signed legislation in 2010 to create the Consumer Financial Protection Bureau, he said the new agency had one priority: “looking out

March 1, 2024

Brachytherapy for Prostate Cancer Linked to Higher Risk of Second Pelvic Malignancy

Pelvic second malignancy occurred twice as often after brachytherapy for prostate cancer as compared with radical prostatectomy, a large retrospective review showed. Second pelvic malignancy

April 24, 2024

BIO’s top lobbyist exits, signaling reorganization

WASHINGTON — The biotech industry’s largest trade group has parted ways with its top lobbyist, the group confirmed to STAT, adding to a recent bout

April 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.